x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243086
| Product Information | |
|---|---|
| CAS No. | 1001419-18-6 |
| Formula | C26H33N6O7P |
| Molecular Weight | 572.55 |
| SMILES | O=C(NC1=NN(CP(OCC)(OCC)=O)C=C1)C2=CC(OC(C)C)=CC(OC3=NC=C(C(N4CCC4)=O)N=C3)=C2 |
| Target | Glucokinase |
| Product Description | BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC50 of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | White to off-white |
| Purity | 99.39% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
